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+39 091 23864244.Abstract. Medication-related osteonecrosis of the jaw (MRONJ) is an adverse drug
reaction that affects the mandible and maxilla of patients exposed to bone-targeting
agents such as anti-resorptive and anti-angiogenic agents. Several MRONJ cases have
been reported after dental extractions in patients under treatment with anti-angiogenic
agents, including receptor activator of nuclear factor kB ligand (RANKL) inhibitor,
anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibody,
mammalian target of rapamycin (mTOR) inhibitors, and tyrosine kinase inhibitors
(TKIs). The aim of this article was to describe an original case of lenvatinib-related
osteonecrosis of the jaw in a patient affected by thyroid cancer. A 58-year-old man
diagnosed with Hurthle cell thyroid cancer, who was undergoing treatment with
lenvatinib, developed maxillary osteonecrosis after a dental extraction. No other
concomitant local or systemic risk factors for MRONJ were present. With new cancer
therapies applied every year, it is important to note this novel case of lenvatinib
osteonecrosis of the jaw in a patient undergoing cancer treatment.Key words: lenvatinib; osteonecrosis of the
jaw; MRONJ; dental extraction.
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(MRONJ) is a relatively uncommon ad-
verse drug reaction, described as the pro-
gressive destruction and death of bone. It
affects the mandible and maxilla of patients
exposed to several medications that are
known to increase the risk of disease.
MRONJ often develops after exposure
to anti-resorptive drugs. These agents,
defined as bone-targeting agents, are usu-
ally applied in oncology for the prevention
of skeletal-related events in patients withbone metastases or myeloma. The anti-
resorptive agents mainly include bispho-
sphonates and denosumab. However,
new bone-targeting agents with no anti-
resorptive properties have been introduced
in recent years, including anti-angiogenic
agents (e.g., receptor activator of nuclear
factor kB ligand (RANKL) inhibitor, anti-
vascular endothelial growth factor (anti-
VEGF) monoclonal antibody, mammalian
target of rapamycin (mTOR) inhibitors,
and small molecule tyrosine kinase inhi-bitors (TKIs)), and anti-angiogenic agents
have also been associated with the devel-
opment of MRONJ1–5.
The diagnosis of MRONJ is based on the
patient’s medical and medication history and
on the clinical–radiological features of ne-
crotic bone (exposed or not exposed)1,3,6,7.
The case of a patient under treatment
with lenvatinib for progressive Hurthle
cell thyroid cancer, who developed
MRONJ with no history of anti-resorptive
treatment, is described below.ation of Oral and Maxillofacial Surgeons. This is an
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Fig. 1. Left-sided maxillary MRONJ: (a) (b) clinical views; (c) panoramic X-ray; (d) (e) (f) computed tomography scan sections.Case report
A 58-year-old man was referred by his
dentist for a long-standing non-healing
socket in the maxilla after a dental extrac-
tion. In 2015, the patienthadbeendiagnosed
with Hurthle cell thyroid cancer and had
undergone a total thyroidectomy, followed
by adjuvant radiotherapy. The following
year, the patient had developed pulmonary
metastases identified by dual positron emis-
sion tomography/computed tomography
(PET/CT) scan and confirmed by lung bi-
opsy. Subsequently the patient was sub-
jected to first-line chemotherapy (i.e.,
doxorubicin and cisplatin-based), and he
was given oral cyclophosphamide and
methotrexate from April 2016.
In February 2017, due to progressive
disease of the lungs, the patient was trea-
ted with lenvatinib (24 mg orally once
daily for 1 month). Then, due to the de-
velopment of severe arthralgia and muscle
cramps with ambulation difficulties, the
lenvatinib dose was reduced to 14 mg
once daily. After 12 months of lenvatinib
intake, the maxillary left first molar was
extracted because of deep caries. Healing
of the socket was never achieved.
Two months after the dental extraction,
intraoral examination revealed clinical
signs of MRONJ. Bone that could be
probed through two intraoral fistulas was
present, associated with purulent exuda-
tion and chronic pain (Fig.1a, b). A pan-
oramic X-ray showed incomplete bone
remodelling in the post-extraction socket(Fig. 1c). Further assessment by CT scan
showed focal osteosclerosis of the jaw
associated with persisting alveolar socket
and cortical disruption (Fig. 1d–f). These
signs were consistent with MRONJ, which
was classified as stage I according to the
American Association of Oral and Maxil-
lofacial Surgeons (AAOMS) criteria and
also the Italian consensus3,6,7.
Treatment with lenvatinib was discon-
tinued by the oncologist and the patient
was treated medically with a combination
of ampicillin and sulbactam (1 g intramus-
cularly twice daily for 7 days) and metro-
nidazole (500 mg orally three times daily
for 7 days), associated with the use of
chlorhexidine 0.2% mouthwash (30 ml
swished for up to 60 seconds, three times
daily for 14 days) and sodium hyaluronate
(local application three times daily for 14
days). At the latest follow-up, after 6
months, the patient was asymptomatic
and the intraoral fistulas had healed.
Discussion
Since 2003, most cases of MRONJ have
been related to the use of bisphosphonates.
However, recent studies have shown that
other anti-resorptive agents (i.e., denosu-
mab) and anti-angiogenic agents (e.g., inhi-
bitors or TKIs) can be associated with
MRONJ1–5. To date, the majority of
MRONJ cases described in the literature
have been related to local risk factors, com-
monly dental extraction1,3,8. However, in
the presence of dental diseases that cannototherwise be resolved, tooth extraction with
standardized protocols may actually de-
crease the risk of MRONJ development8,9.
Lenvatinib is a small-molecule inhibitor
that inhibits receptor tyrosine kinases
(RTKs) of vascular endothelial growth
factor receptors (e.g., VEGFR1, VEGFR2,
VEGFR3), as well as other RTKs includ-
ing fibroblast growth factor receptor,
platelet-derived growth factor receptor al-
pha, KIT, and RET. These RTKs are
responsible for pathogenic angiogenesis,
tumour growth, and cancer progression.
In Europe, lenvatinib was first approved
for the treatment of adult patients with
progressive, locally advanced or metastat-
ic, differentiated (e.g., papillary/follicular/
Hurthle cell) thyroid carcinoma that is
refractory to radioactive iodine, in 2015.
This approval was based on the results of
the pivotal phase 3 study of lenvatinib
(E7080) in differentiated cancer of the
thyroid (SELECT), where lenvatinib sig-
nificantly prolonged progression-free sur-
vival vs. placebo (median progression-free
survival 18.3 vs. 3.6 months; hazard ratio
0.21, 99% confidence interval 0.14–0.31;
P < 0.001).10 In the SELECT trial, nearly
all of the 392 patients enrolled experi-
enced an adverse event.
The most common adverse effects of len-
vatinib are headache, hypertension, protein-
uria, dysphonia, palmar-plantar
erythrodysesthesia  syndrome, arthralgia or
myalgia, decreased appetite, and gastroin-
testinal disturbances. Serious events, includ-
ing QT prolongation, posterior reversible
1532 Mauceri et al.leukoencephalopathy syndrome, hepatic, re-
nal, or cardiac failure, intracranial tumour
haemorrhage, gastrointestinal perforation or
fistula, and arterial thromboembolism, have
also been reported. Of note, delayed wound
healing is also a recognized adverse effect of
lenvatinib10,11.
Within the group of TKIs, sorafenib, suni-
tinib, and cabozantinib already carry a rec-
ognized risk of MRONJ development2,4,5.
The patient case presented here is novel and
appears to be the first published case of
lenvatinib-associated osteonecrosis of the
jaw. This patient developed the common
clinical-radiological features of MRONJ,
without prior exposure to anti-resorptive
and/or anti-angiogenic drugs related to
osteonecrosis of the jaw. The patient was
only exposed to dental extraction and had no
other concomitant recognized local or sys-
temic risk factors for MRONJ. While await-
ing new reports to confirm the occurrence of
lenvatinib-associated osteonecrosis of the
jaw, it is considered that due to it mechanism
of action, lenvatinib may be a further anti-
cancer agent associated with this condition.
Side effects of lenvatinib can be observed
at any time following lenvatinib initiation,
and these side effects are caused by the
effects of lenvatinib on VEGF inhibition10.
VEGF is an important mediator of the angio-
genic process; it is required for bone forma-
tion and repair and is the main signal between
osteoblast cells and endothelial cells. In ad-
dition, the high bone turnover of the jaws
makes this area reliant on the effective func-
tion of osteoblasts and osteoclasts.
The data presented herein are consistent
with those of other reports highlighting the
important role of anti-angiogenic drugs
that act directly on VEGF (e.g., bevacizu-
mab) in predisposing patients to osteone-
crosis of the jaw, regardless of their
association with bisphosphonates.
As new drugs with multi-target actions
are applied in anticancer therapy every
year, clinicians need to pay attention to
oral health problems and their manage-
ment during the use of these new thera-
pies, in order to reduce outbreaks of
MRONJ and consequently improve the
quality of life of patients who are already
afflicted by serious primary pathologies.
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